reports
- Simen Mortensen
Kojamo (Buy, TP: EUR12.00) - Occupancy is improving
Kojamo reported a Q1 EPRA occupancy rate of 92.8% (+40bp YOY), with further improvement in March to 93.5%, driven by lower tenant turnover and incentives for new signings. EBIT exceeded our estimate by 2% and Infront consensus by 3%, but EPRA earnings missed our forecast (by 10%) due to higher funding costs. Despite the EPRA EPS miss, Kojamo reiterated its full-year FFO guidance. We have raised our adj. EPS (FFO) forecasts for 2025−2027 by 2–5% due to lower market interest rates. We reiterate ou...
- Ole Martin Westgaard
Norwegian Air Shuttle (Buy, TP: NOK16.00) - Positive 2025 outlook
While underlying Q1 results were weaker than we expected, we still see a positive outlook for 2025, with solid bookings, a narrowed CASK guidance supported by a NOK1bn profit improvement programme by 2026, FX, and fuel tailwinds. We reiterate our BUY, but have cut our target price to NOK16 (17) on estimate reductions.
- Simen Mortensen
Veidekke (Hold, TP: NOK150.00) - Q1 was a supportive non-event
Q1 EBIT was NOK-43m, slightly below our forecast, with low seasonal profits due to winter effects in the asphalt operations. This is a seasonally insignificant quarter for the company due to the winter season, and, for context, we expect 2025 EBIT of NOK1.7bn. Order intake and backlog were the Q1 strong points. With the results and commentary supportive of our earnings forecasts, we have made minor estimate changes on the group level and reiterate our HOLD, but have cut our target price to NOK15...
- Rune Majlund Dahl
Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst
Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).
- Niclas Gehin
Kongsberg Gruppen (Sell, TP: NOK1250.00) - Expectations are set too hi...
We have downgraded Kongsberg Gruppen to SELL (HOLD) and lowered our target price to NOK1,250 (1,450). We believe the 2025e P/E of 46x overstates its growth capabilities 1) on an absolute basis, in a scenario where all of NATO reaches defence spending of 3.3% of GDP; and 2) compared to other defence companies as, in our view, the market appears to miss that only 20% of its 2024 sales were from European defence spending.
- Jesper Ingildsen
ChemoMetec (Buy, TP: DKK640.00) - Solid Q3, but with mixed elements
With c26% revenue growth, Q3 was stronger than expected, with a solid beat on recurring revenue lines, although instruments fell just shy of our forecast, mainly related to new product launches that, despite a significant rise in customer validations in progress, take time. The maintained guidance implies only c5% YOY growth in Q4, but we believe management is being conservative. We reiterate our BUY and DKK640 target price.
- Jesper Ingildsen
Ambu (Buy, TP: DKK144.00) - Possibly isolated softness
Q2 was below our forecast, but the softness might be isolated to Q2 on what could be Chinese competitors dumping stock ahead of tariffs, which could become a tailwind. Notably, the 2024/25 guidance was maintained and includes headwinds from FX and tariffs. We reiterate our BUY, but have cut our target price to DKK144 (155).
- Niclas Gehin
Elopak (Hold, TP: NOK44.00) - A quarter without surprises
Elopak reported its first quarter with revenue above EUR300m, translating to EBITDA of EUR45m, 3% above our estimate and 1% above consensus. Despite a strong top line, margins contracted 2.6%-points QOQ due to pre-production costs related to its new facility in Little Rock and continued imports from JVs and Europe. We have adjusted our 2026–2027e EPS by 2–1% and reiterate our HOLD, but have increased our target price to NOK44 (40), mainly due to lower tariff concerns and multiples expansion amon...
- Ole Martin Westgaard
Sats (Hold, TP: NOK37.00) - Time for a breather
Q1 was slightly below expectations and the CMD targets were broadly in line with our forecasts and consensus. We have raised our target price to NOK37 (34) on higher estimates but have downgraded to HOLD (BUY), as we find the valuation fair following the recent strong share price performance.
- Ole Martin Westgaard
Schibsted (Sell, TP: NOK290.00) - Muted growth continues
The Q1 results were above expectations on lower-than-expected costs, while growth continued to be muted. We reiterate our SELL as we continue to find the valuation high relative to growth prospects, but have raised our target price to NOK290 (280) on increased estimates.
- Niclas Gehin
Tomra (Sell, TP: NOK130.00) - Disappointing Recycling orders
We have reduced our 2026-2027e Recycling EBITA by c6%, due to lower-than-expected Q1 EBITA and order intake. With several EU markets moving closer to implementing a deposit return system, we have raised our 2026–2027e Collection EBITA by c5%. The net effect is an increase of 2–3% for the group 2026–2027e EPS, and we have thus raised our target price to NOK130 (120). We reiterate our SELL, as we believe Tomra’s valuation does not reflect its growth prospects.
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK900.00) - Accelerated Wegovy roll-out ahead
Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.
- Simen Mortensen
Skanska (Buy, TP: SEK255.00) - Volatile miss in Q1
Q1 EBIT missed, as the Residential and Commercial Development divisions had weaker-than-expected results. We have reduced our recovery expectations for these segments due to continued softness in Nordic housing sales and a slow recovery in US commercial property development. However, we still see upside potential in our SOTP-based valuation and reiterate our BUY. Nevertheless, based on our lowered forecasts, we have reduced our target price to SEK255 (270).
- Rune Majlund Dahl
Lundbeck (Buy, TP: DKK48.00) - Focus on Vyepti sales
We forecast Q1 sales c0.5% above consensus and an adj. EBITDA margin of 31.3%. We expect the strategic brands sales to rise by 18.3% YOY, including Vyepti sales of DKK913m (c2.2% above consensus). We forecast unchanged 2025 guidance for CER figures. From the pipeline, the FDA AdCom for Rexulti in PTSD is still unscheduled and the PROCEED trial has recently been expanded to additional IV doses. We reiterate our BUY, but have cut our target price to 48 (56).
- Ole Martin Westgaard
Norwegian Air Shuttle (Buy, TP: NOK17.00) - April traffic statistics
We consider this a slightly positive report for Norwegian Air Shuttle, including figures more or less in line with expectations, with a marginally lower yield offset by a higher load, and positive outlook comments with regard to summer bookings. We expect only minor changes to consensus 2025e adj. EBITDA, and believe a neutral to slightly positive share price reaction is warranted.
- Simen Mortensen
Peab (Hold, TP: SEK85.00) - Q1 EBIT broadly as expected
Peab reported a Q1 seasonal EBIT loss (as expected), driven by winter-related effects in Industry. We have lowered our 2025e EPS due to the low tax rate in Q1, despite a broadly in-line underlying performance. We have slightly raised our revenue and EPS forecasts for 2026–2027 by c1%. We continue to see better risk/reward in peers and reiterate our HOLD and SEK85 target price.
- Ole Martin Westgaard
Schibsted (Sell, TP: NOK280.00) - Prisjakt sold at low price
Schibsted has signed an agreement to sell Prisjakt to eEquity for SEK500m. We find the price low, at c40% of our SOTP value, but find it positive that the company continues to simplify its portfolio to focus on Nordic Marketplaces. We expect a slightly negative share price reaction.
- Ole Martin Westgaard
Norwegian Air Shuttle (Buy, TP: NOK17.00) - April traffic statistics p...
April’s traffic statistics are due at 08:00 CET on 7 May. We are positive ahead of the report, expecting a strong yield recovery supported by Easter timing effects and easing capacity growth. We reiterate our BUY and have raised our target price to NOK17 (15) on positive estimate changes on our revised fuel and USDNOK assumptions.
- Jesper Ingildsen
ChemoMetec (Buy, TP: DKK640.00) - Likely solid Q3 but no pre-release
We previously expected ChemoMetec to have raised its full-year guidance ahead of the Q3 results, but assume the weaking USD and greater uncertainty from tariffs led it to refrain. We still expect a solid Q3, helped by new product launches, while in general we expect tariffs to have minimal effect on its costs, considering its location of production and high gross margin. We reiterate our BUY, but have lowered our target price to DKK640 (675).
- Jesper Ingildsen
Ambu (Buy, TP: DKK155.00) - Another strong quarter
We forecast Ambu to have another strong quarter, with c14% organic growth (we are above consensus) and continued solid margin progression. Despite tariffs, we expect the company to maintain its full-year guidance, but possibly increase the top-line guidance later in the year. We will also look for comments on the impact of tariffs on margins in the coming years. We reiterate our BUY, but have lowered our target price to DKK155 (165).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.